Vineet Laboratories Ltd (NSE: VINEETLAB, BSE: 543298) is a Hyderabad, Telangana-based company in the Medicinal Chemicals and Botanical Products industry. With a market capitalisation of ₹72 Cr, it ranks #3,514 by market cap among the 6,197 Indian listed companies on FinBizNet, and #72 of 86 in Medicinal Chemicals and Botanical Products. At ₹37.75 (as of 16 Nov 2026), the share price is 16.5% below its 52-week high of ₹45.20 and 35.0% above its 52-week low of ₹27.96. The share price is down 15.3% over one year and down 1.7% over three months.
| Current Price | ₹37.75 |
|---|---|
| Market Cap | ₹72 Cr |
| NSE Symbol | VINEETLAB |
| BSE Code | 543298 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products |
| P/E Ratio | 38 |
| Return on Equity | 3.68% |
| Return on Assets | 3.52% |
| 52-Week Range | ₹27.96 – ₹45.20 |
| 1-Year Price Change | -15.3% |
| 3-Month Price Change | -1.7% |
| Beta (1Y) | 0.22 |
| Dividend Yield | 0.00% |
| Headquarters | Hyderabad, Telangana |
| Website | vineetlabs.co.in |
| Revenue | ₹14 Cr |
|---|---|
| Net Profit | ₹0 Cr |
| Net Margin | 0.8% |
| EPS (Basic) | ₹0.06 |
| Basis | standalone |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Vineet Laboratories Ltd reported revenue of ₹14 Cr in Q2 FY27, down 18.6% from ₹17 Cr in Q2 FY26 and up 36.5% from ₹10 Cr in Q1 FY27. It posted a net profit of ₹0 Cr for the quarter, against a net profit of ₹0 Cr in Q2 FY26 (down 70.0%). Across the 7 quarters from Q4 FY25 to Q2 FY27, quarterly revenue ranged from ₹7 Cr (Q1 FY26) to ₹19 Cr (Q4 FY26). The company reported a net loss in 2 of these 7 quarters.
| Quarter | Revenue | Net Profit | Net Margin |
|---|---|---|---|
| Q2 FY27 | ₹14 Cr | ₹0 Cr | 0.8% |
| Q1 FY27 | ₹10 Cr | ₹2 Cr | 14.5% |
| Q4 FY26 | ₹19 Cr | ₹1 Cr | 6.5% |
| Q3 FY26 | ₹16 Cr | ₹1 Cr | 5.4% |
| Q2 FY26 | ₹17 Cr | ₹0 Cr | 2.3% |
| Q1 FY26 | ₹7 Cr | −₹1 Cr | −11.7% |
| Q4 FY25 | ₹14 Cr | −₹11 Cr | −74.8% |
Standalone figures (₹ crore, XBRL filings).
Promoters held 5.98% of Vineet Laboratories Ltd's shares as of Sept 2026, against 12.46% in Dec 2025 (−6.48 percentage points). Delivery averaged 70.6% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).
Vineet Laboratories Limited engages in the research, development, manufacture, and sale of active pharmaceutical ingredients (API), intermediates, and fine chemicals primarily in India. The company offers intermediates of Lopinavir, Ritonavir, Efavirenz, Nadolol, Glimepiride, Celecoxib, Piroctone Olanine, and other API intermediates. It also provides fine chemicals and reagents, such as isopropyl-beta-d-thiogalactopyranoside, n-butyl lithium, 4-nitrophenyl phosphate disodium salt, 5-bromo-4-chloro-3-indolyl-beta-d-galactopyranoside, 5-acetyl thiophene-2-carboxilic acid, 4-chlorobutyryl chloride, n-butyl magnesium chloride, 3-furaldehyde, 3-bromofuran, n-butylnitrite, ethyldiazo acetate, phenylboronic acid, 6-aminouracil, and 1-methyl-imidazole-2-carboxaldehyde. The company was incorporated in 2016 and is based in Hyderabad, India.
1. Drug Intermediates & Bulk Dugs-This segment engages in the research, development, and manufacture of active pharmaceutical ingredients and fine chemicals.
1. Active Pharmaceuticals Ingredient and Intermediates-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4,56,425 Cr | 39.5 | 14.72% | ₹16,199 Cr | +11.2% |
| Laurus Labs Ltd | ₹1,31,242 Cr | 145.6 | 17.74% | ₹2,206 Cr | +146.8% |
| Zydus Lifesciences Ltd | ₹1,19,651 Cr | 24.1 | 18.32% | ₹7,910 Cr | +26.0% |
| Dr.Reddys Lab | ₹1,15,464 Cr | 26.9 | 11.52% | ₹8,698 Cr | +14.5% |
| Cipla Limited | ₹1,14,712 Cr | 29.3 | 11.74% | ₹7,404 Cr | -7.6% |
| Mankind Pharma | ₹1,09,870 Cr | 57 | 12.45% | ₹4,338 Cr | +16.7% |
| Aurobindo Pharma Ltd. | ₹1,05,150 Cr | 30 | 9.93% | ₹10,263 Cr | +59.8% |
| Lupin Ltd | ₹92,087 Cr | 17.3 | 26.91% | ₹7,827 Cr | +0.4% |
| Vineet Laboratories Ltd | ₹72 Cr | 38 | 3.68% | ₹14 Cr | -15.3% |
Listed by market capitalisation. Ratios are shown for context only.
Vineet Laboratories Ltd is trading at ₹37.75, with a market capitalisation of ₹72 Cr.
Vineet Laboratories Ltd operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products).
Vineet Laboratories Ltd has a P/E of 38 and a return on equity of 3.68%.
Vineet Laboratories Ltd is listed on the NSE under the symbol VINEETLAB and on the BSE under the scrip code 543298.
Vineet Laboratories Ltd's share price is down 15.3% over one year and down 1.7% over three months. Its 52-week range is ₹27.96 to ₹45.20.
In Q2 FY27, Vineet Laboratories Ltd reported revenue of ₹14 Cr and net profit of ₹0 Cr, with basic EPS of ₹0.06 (standalone, parsed from the company's exchange filing).
Vineet Laboratories Ltd reported revenue of ₹14 Cr in Q2 FY27, down 18.6% from ₹17 Cr in Q2 FY26 and up 36.5% from ₹10 Cr in Q1 FY27.
Promoters held 5.98% of Vineet Laboratories Ltd's shares as of Sept 2026, against 12.46% in Dec 2025 (−6.48 percentage points).
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.